SYNLAB Valuation
Is 0A9B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0A9B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0A9B (€11.09) is trading above our estimate of fair value (€1.09)
Significantly Below Fair Value: 0A9B is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0A9B?
Key metric: As 0A9B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0A9B's PE Ratio? | |
|---|---|
| PE Ratio | 27.1x |
| Earnings | €89.35m |
| Market Cap | €2.42b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 12.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 0A9B's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.1x | ||
IDHC Integrated Diagnostics Holdings | 13.8x | 23.7% | US$226.7m |
MDC Mediclinic International | 21.9x | 10.7% | UK£3.7b |
KOO Kooth | 14.1x | 11.0% | UK£59.6m |
SPI Spire Healthcare Group | 30.8x | 26.9% | UK£871.1m |
0A9B SYNLAB | 27.1x | n/a | €2.4b |
Price-To-Earnings vs Peers: 0A9B is expensive based on its Price-To-Earnings Ratio (27.1x) compared to the peer average (20.8x).
Price to Earnings Ratio vs Industry
How does 0A9B's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0A9B is expensive based on its Price-To-Earnings Ratio (27.1x) compared to the European Healthcare industry average (18.4x).
Price to Earnings Ratio vs Fair Ratio
What is 0A9B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 27.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0A9B's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arjo
SEK 9.0b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 33.08
7D
-5.8%
1Y
-11.0%
Guerbet
€334.1m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€26.80
7D
-7.7%
1Y
47.7%
LNA Santé
€243.4m
Engages in the management and operation of health establishments.
0OR2
€24.00
7D
-5.5%
1Y
18.5%